These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19774214)

  • 1. Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review.
    Monnier A
    Ther Clin Risk Manag; 2009 Oct; 5(5):725-38. PubMed ID: 19774214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
    Dunn C; Keam SJ
    Pharmacoeconomics; 2006; 24(5):495-517. PubMed ID: 16706574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early recurrence risk: aromatase inhibitors versus tamoxifen.
    Bria E; Carlini P; Cuppone F; Vaccaro V; Milella M; Cognetti F
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1239-53. PubMed ID: 20735310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials.
    Markopoulos CJ
    Cancer Metastasis Rev; 2010 Dec; 29(4):581-94. PubMed ID: 20830503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM; Gligorov J
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: what do we really know?
    Chung CT; Carlson RW
    Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S18-23. PubMed ID: 15347435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
    Paepke S; Jacobs VR; Ohlinger R; Warm M; Kümmel S; Thomas A; Harbeck N; Kiechle-Bahat M
    J Cancer Res Clin Oncol; 2007 Dec; 133(12):905-16. PubMed ID: 17805570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aromatase inhibitors in early breast cancer.
    Chung CT; Carlson RW
    Curr Treat Options Oncol; 2003 Apr; 4(2):133-40. PubMed ID: 12594939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
    Mouridsen HT; Robert NJ
    MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
    Ellis MJ; Rigden CE
    Curr Med Res Opin; 2006 Dec; 22(12):2479-87. PubMed ID: 17257462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.